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Abstract
The associations of acute HIV infection (AHI) and other predictors with transmitted drug
resistance (TDR) prevalence were assessed in a cohort of HIV-infected, antiretroviral-naïve
patients. AHI was defined as being seronegative with detectable HIV RNA. Binomial regression
was used to estimate prevalence ratios and 95% confidence intervals (CIs) for associations with
TDR. Among 43 AHI patients, TDR prevalence was 20.9%, while prevalence was 8.6% among
677 chronically-infected patients. AHI was associated with 1.9 times the prevalence of TDR (95%
CI: 1.0, 3.6) in multivariable analysis. AHI patients may represent a vanguard group that portends
increasing TDR in the future.
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Introduction
Transmitted drug resistance (TDR) may lead to a more rapid decline in CD4 cell counts
prior to combination antiretroviral therapy (cART) initiation, and may increase the risk of
virologic failure following cART initiation1–3. Therefore current HIV treatment guidelines
recommend resistance testing at entry into HIV care and at cART initiation4.
TDR prevalence in the U.S. and internationally has been estimated to be between 8 and
15%5, 6; however, little is known about TDR in the Southeastern U.S., where the HIV
epidemic continues to grow7. TDR prevalence may be higher among patients with acute
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HIV infection (AHI), than patients with chronic HIV infection (CHI)8, 9; but no direct
comparisons have been made as AHI is typically either unidentified or crudely defined in
large populations. Notwithstanding efforts at increasing HIV testing and early linkage to
HIV care10, the vast majority of patients initiate HIV care with CD4 cell counts less than
500 cells/mL11. Therefore understanding the relationship between duration of HIV infection
and TDR detection remains relevant. Knowledge of trends in TDR can guide clinical
decisions about resistance testing and cART options, and may also inform community
prevention efforts by identifying risk factors for acquiring TDR. In this study we used the
University of North Carolina (UNC) Center for AIDS Research HIV Clinical Cohort
(UCHCC) to characterize patients with TDR, evaluate trends over time, and contrast
prevalence by HIV infection duration.
Methods
Patients at least 18 years of age participating in the UCHCC who initiated HIV care between
January 1999 and September 2010 were eligible for this study. The UCHCC and its
procedures have been described previously12. Briefly, information is collected on HIV
diagnosis date, HIV transmission risk factors, antiretroviral (ARV) start and stop dates, and
resistance reports through semi-annual standardized clinical record reviews. Demographic
information (age, sex, and race), and laboratory information including CD4 cell counts and
HIV viral loads are extracted from institutional electronic databases. For this study,
laboratory results collected nearest to the genotype sample date were used to obtain values
for CD4 cell counts and HIV viral loads. AHI was defined as either: a combination of non-
reactive enzyme-linked immunosorbent assay (ELISA) or a negative or indeterminate
Western blot (WB) paired with a positive HIV RNA or p24 antigen test, or a negative
ELISA and WB less than 45 days before a documented positive ELISA or WB8, 13. All
patients participating in the UCHCC provided informed consent. Ethical approval for this
study was obtained from the UNC Institutional Review Board.
Patients were included who had at least one available genotype prior to cART initiation. Of
the 720 eligible patients, 408 had genotypes available through routine clinical care and 312
patients had genotypes conducted on archived specimens. Population or “bulk” genotyping
was conducted using commercially available assays, with over 90% of assays using HIV
Genosure and HIV Genosure Plus (Laboratory Corporation of America, Research Triangle
Park, North Carolina, USA). TDR was defined as the detection of any of the surveillance
drug resistance mutations (SDRMs) listed by the World Health Organization14. We further
characterized SDRMs into nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside
reverse transcriptase inhibitor (NNRTI), or protease inhibitor (PI) mutations. Dual-class
resistance was defined as the detection of at least one SDRM from two of the three drug
classes considered: NRTI, NNRTI, and PI. Triple-class resistance was defined as the
detection of at least one SDRM from all three drug classes. Integrase inhibitor resistance
was not assessed.
Prevalence of TDR was calculated as the number of patients with detectable SDRMs divided
by all patients with an available genotype; 95% confidence intervals (CI) were calculated
using the exact binomial method. We assessed TDR prevalence over calendar time using the
Cochran-Armitage trend test. Multivariable log-binomial regression was used to estimate
adjusted prevalence ratios (PR) and 95% CIs of TDR across patient characteristics 15.
Covariates were selected based on a priori knowledge and associations with AHI and TDR
in the data. All analyses were conducted using SAS 9.2 statistical software (SAS Institute,
Cary, North Carolina, USA).
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Of the 720 patients included in this study, 71% were male, 57% black, and 28% white; 43%
of the patients were men who have sex with men (MSM), and 9% reported prior injection
drug use (IDU). The median year of genotype sample date was 2005 (interquartile range,
IQR: 2001–2007) and the average time from HIV diagnosis to genotype was 60 days (IQR:
22–280). The median CD4 cell count at genotype testing was 256 cells/mm3 (IQR: 62–454)
and the median HIV RNA level was 4.8 log10 copies/mL (IQR: 4.2–5.3). Almost all patients
were infected with HIV subtype B with <1% non-B subtypes. Forty-three patients were
identified as AHI. AHI compared to CHI patients were more likely to be male (88 versus
70%, p=0.02), MSM (81 versus 41%, p<0.001), have higher CD4 cell counts (median 515
versus 236 cells/mm3, p<0.001) and HIV RNA levels (median 5.2 versus 4.8 log10 copies/
mL, p=0.003). AHI patients had more recent genotypes (median year 2006 versus 2005,
p<0.001) and shorter time from diagnosis to genotype (median 0.6 months versus 2.2
months, p<0.001).
The overall prevalence of TDR was 9.3% (95% CI: 7.3, 11.7): 1.5% with dual-class drug
resistance and none with triple-class drug resistance. NNRTI resistance was most common
(5.7% of all patients), while PI resistance was least common (1.5% of all patients). The most
common SDRMs for the NRTI, NNRTI, and PI classes were D67N (1.1%), K103N (4.4%),
and L90M (1.3%), respectively. Twenty-one percent (n=9) of AHI patients had evidence of
TDR. Eight AHI patients had NNRTI mutations, six patients had K103N, and one each had
Y188L and K103S. One AHI patient had a PI mutation (L90M) and none had dual class
resistance. Nine percent (n=58) of CHI patients had TDR. Thirty-three CHI patients had
NNRTI resistance; the most frequent were K103N (n=26), G190A (n=7), and K101E (n=3).
The most common NRTI and PI mutations detected among CHI patients were D67N (n=8)
and L90M (n=8), respectively. Eleven CHI patients had dual class resistance.
Patients with AHI had 2.4 times the prevalence of TDR than patients with CHI (95% CI:
1.3, 4.6; Table 1). The prevalence of TDR had a relative increase of 7% with each 100 CD4
cell count increase (95% CI: 0%, 14%), and was higher among MSM. Prevalence of TDR
increased with calendar time (P=0.01 for trend; Figure 1A). This was primarily due to
increases in NNRTI TDR with a relative increase in NNRTI TDR of 20% with each
additional calendar year (95% CI: 10, 30; Figure 1B).
In multivariable analyses, after adjusting for age, MSM, and calendar year of genotype test,
AHI remained positively associated with TDR (PR: 1.9; 95% CI: 1.0, 3.6). Adjustment for
additional variables including sex, race, CD4 cell count and HIV RNA level did not
meaningfully change the PR estimate (PR: 1.8; 95% CI: 0.9, 3.7). In further multivariable
analyses we did not identify other factors that were independently predictive of TDR among
all patients.
Results were stratified by infection duration to assess whether demographic and clinical
characteristics predicted TDR differently among AHI versus CHI patients. Consistent with
our overall results, TDR prevalence was higher in more recent calendar years within both
strata (AHI: 1999–2005=8%, 2006–2010=28%; CHI: 1999–2005=7%, 2006–2010=11%).
NNRTI prevalence was also higher in more recent calendar years within both strata (AHI:
1999–2005=8%, 2006–2010=24%; CHI: 1999–2005=3%, 2006–2010=7%). Among AHIs,
TDR prevalence was 1.3 times higher with each passing calendar year (95% CI: 0.9, 1.8,
P=0.13 for trend) and prevalence was 1.1 times higher with each calendar year increase in
CHIs (95% CI: 1.0, 1.2, P<0.01 for trend). MSM appeared predictive of TDR among CHI
patients, but was not predictive of TDR among AHI patients. No other factors appeared
YANIK et al. Page 3













predictive within either strata of infection duration, though power was not sufficient to
conduct multivariable analyses.
Discussion
We observed a high prevalence of TDR in this Southeastern US cohort. Prevalence was
highest for NNRTI mutations and lowest for PI mutations. As our study period began after
the first case reports of TDR for NRTIs (1993), NNRTIs (1997), and PIs (1998), all of these
mutations were expected to be present in our population from the beginning of the study
period, at least at low levels16. TDR prevalence rose over calendar time in our population,
with the latest estimates similar to prevalence estimates from recent US surveillance
data6, 17. By contrast, studies in Europe have shown stabilizing and possibly decreasing
trends in TDR prevalence in more recent years5.
Within our study, the rise in TDR across calendar time was mainly due to a rise in NNRTI
mutations. This may be due in part to a rise in use of NNRTI-based fixed-dose combination
regimens during this same time interval. This could also be evidence of the persistence of
common NNRTI mutations such as K103N which are known to be long-lived even in the
absence of ARV exposure18, 19. Persistence of TDR may be longer in the genital tract20,
which can lead to reservoirs of resistance and transmission chains of TDR among
antiretroviral naïve individuals21. As such, the observed increase in TDR prevalence may be
due to onward transmission from individuals failing cART, individuals who are cART naive
with TDR, or both.
Our most notable finding was the substantial difference in TDR prevalence by infection
duration. A comparison of TDR by infection duration has not been made in larger studies
because of the lack of a precise definition of AHI such as was available in our study. AHI
patients had over twice the prevalence of TDR compared to CHI patients, largely driven by
a higher frequency of NNRTI mutations. Several hypotheses may explain the association of
infection duration with TDR. The lower prevalence of TDR in CHIs compared to AHIs may
be a result of the reversion of mutations over time. We were unable to assess changes in
detection of SDRMs over time within individual ARV naïve patients. Reversion of
mutations to wild type has been observed, although certain SDRMs may persist despite the
absence of ARV exposure18, 19. NNRTI mutations, specifically K103N, reduce replicative
capacity only moderately and thus can persist for long periods of time18. Additionally,
minority variants may persist and have a meaningful influence on treatment response22.
Genotype testing shortly after AHI diagnosis may be informative for clinicians even if
immediate ARV initiation is not expected, as detectable mutations in AHI may possibly
persist as minority variants in CHI.
The association of infection duration with TDR could also be due to differences between
AHI and CHI patients not accounted for in this analysis. Individuals with high risk behaviors
not measured in this study may be more likely to be a part of sexual networks with TDR and
may undergo more frequent HIV testing increasing the probability of being diagnosed with
AHI23. Some CHI patients may have been infected before the widespread use of cART,
while AHI patients with more recent infection dates may have been infected when there
were higher levels of SDRMs circulating in the HIV population. Given the high prevalence
of NNRTI mutations among AHI patients and the increasing trend in NNRTI mutation
prevalence over time, patients with AHI may serve as a harbinger of future TDR trends in
CHI individuals.
No covariates other than AHI appeared to independently predict TDR. Prior literature has
not identified consistent individual-level risk factors for TDR5, 6, 8, 24, which may be a result
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of patients contracting TDR for heterogeneous reasons, as well as differing treatment
practices and treatment histories by geographic region. The absence of strong predictors of
TDR underscores the importance of genotype testing for all antiretroviral-naïve HIV patients
regardless of demographic or behavioral characteristics.
TDR limits treatment options, increases the risk of poor treatment outcomes2, 3 and results in
onward transmission of resistant virus. The rising prevalence of TDR and high prevalence
among AHI patients suggest that ARV treatment options with higher genetic barriers to
resistance may be indicated. Ongoing monitoring for TDR will remain important in
considering appropriate clinical practices and anticipating future challenges as fewer new
ARVs are developed. Monitoring resistance specifically within the AHI population may
serve as an important tool in forecasting future patterns of drug resistance. Further
investigation into the reasons for differences in TDR prevalence between AHI and CHI
individuals, including in-depth comparisons of risk behaviors and community antiretroviral
use, can optimize the interpretation of TDR monitoring data in both groups in the future.
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A) Prevalence of Transmitted Drug Resistance across calendar time and B) Prevalence of
Non-Nucleoside Reverse Transcriptase Inhibitor Transmitted Drug Resistance across
calendar time
Error bars indicate 95% confidence intervals calculated using the binomial exact test. Gray
dotted line in (A) indicates trend across all calendar years. TDR=Transmitted drug
resistance, n AHI= number of patients with acute HIV infection who had a genotype
obtained in each calendar year, n CHI=number of patients with chronic HIV infection who
had a genotype obtained in each calendar year, NNRTI=Non-nucleoside reverse
transcriptase inhibitor
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